130 related articles for article (PubMed ID: 38837825)
1. Clinical impact of using [
Leupe H; Pauwels E; Vandamme T; Van den Broeck B; Lybaert W; Dekervel J; Van Herpe F; Jaekers J; Cleeren F; Hofland J; Brouwers A; Koole M; Bormans G; Van Cutsem E; Geboes K; Laenen A; Verslype C; Stroobants S; Deroose CM
J Neuroendocrinol; 2024 Jun; ():e13420. PubMed ID: 38837825
[TBL] [Abstract][Full Text] [Related]
2.
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Boeckxstaens L; Dekervel J; Vandamme T; Lybaert W; den Broeck BV; Laenen A; Clement PM; Geboes K; Cutsem EV; Stroobants S; Verslype C; Bormans G; Deroose CM
J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
[No Abstract] [Full Text] [Related]
3. Prospective comparison of [
Boeckxstaens L; Pauwels E; Vandecaveye V; Deckers W; Cleeren F; Dekervel J; Vandamme T; Serdons K; Koole M; Bormans G; Laenen A; Clement PM; Geboes K; Van Cutsem E; Nackaerts K; Stroobants S; Verslype C; Van Laere K; Deroose CM
EJNMMI Res; 2023 Jun; 13(1):53. PubMed ID: 37261615
[TBL] [Abstract][Full Text] [Related]
4. [
Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Dekervel J; Van Cutsem E; Verslype C; Van Laere K; Bormans G; Deroose CM
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [
Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
[TBL] [Abstract][Full Text] [Related]
6. Al[
Haeger A; Soza-Ried C; Kramer V; Hurtado de Mendoza A; Eppard E; Emmanuel N; Wettlin J; Amaral H; Fernández R
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672388
[TBL] [Abstract][Full Text] [Related]
7. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
Calabrò D; Argalia G; Ambrosini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance and clinical impact of
Hou G; Cheng X; Yang Y; Zhao D; Wang G; Zhao H; Zheng R; Wang X; Chen X; Chi Y; Zhang J
Theranostics; 2024; 14(8):3213-3220. PubMed ID: 38855183
[No Abstract] [Full Text] [Related]
9. Preparation and Evaluation of [
Dam JH; Langkjær N; Baun C; Olsen BB; Nielsen AY; Thisgaard H
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296411
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the safety, biodistribution, dosimetry of [
Liu M; Ren C; Zhang H; Zhang Y; Huang Z; Jia R; Cheng Y; Bai C; Xu Q; Zhu W; Huo L
Eur J Nucl Med Mol Imaging; 2024 Jun; ():. PubMed ID: 38878175
[TBL] [Abstract][Full Text] [Related]
11. The Search for an Alternative to [
Waldmann CM; Stuparu AD; van Dam RM; Slavik R
Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
14. 3p-C-NETA: A versatile and effective chelator for development of Al
Ahenkorah S; Murce E; Cawthorne C; Ketchemen JP; Deroose CM; Cardinaels T; Seimbille Y; Fonge H; Gsell W; Bormans G; Ooms M; Cleeren F
Theranostics; 2022; 12(13):5971-5985. PubMed ID: 35966589
[No Abstract] [Full Text] [Related]
15. Clinical Application of 18F-AlF-NOTA-Octreotide PET/CT in Combination With 18F-FDG PET/CT for Imaging Neuroendocrine Neoplasms.
Long T; Yang N; Zhou M; Chen D; Li Y; Li J; Tang Y; Liu Z; Li Z; Hu S
Clin Nucl Med; 2019 Jun; 44(6):452-458. PubMed ID: 30985413
[TBL] [Abstract][Full Text] [Related]
16. (68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.
Khor LK; Loi HY; Sinha AK; Tong KT; Goh BC; Loh KS; Lu SJ
Head Neck; 2016 Apr; 38(4):E76-80. PubMed ID: 26275126
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison of [
Ahenkorah S; Cawthorne C; Murce E; Deroose CM; Cardinaels T; Seimbille Y; Bormans G; Ooms M; Cleeren F
Nucl Med Biol; 2023; 118-119():108338. PubMed ID: 37018875
[TBL] [Abstract][Full Text] [Related]
18. Altered biodistribution of [
van de Weijer T; Bemer F; de Vos-Geelen J; Hermans B; Mitea C; van der Pol JAJ; Lodewick T; Wildberger JE; Mottaghy FM
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2420-2427. PubMed ID: 38403723
[TBL] [Abstract][Full Text] [Related]
19. Automated GMP compliant production of [
Tshibangu T; Cawthorne C; Serdons K; Pauwels E; Gsell W; Bormans G; Deroose CM; Cleeren F
EJNMMI Radiopharm Chem; 2020 Jan; 5(1):4. PubMed ID: 31997090
[TBL] [Abstract][Full Text] [Related]
20. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]